Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Wegovy has been a hugely popular treatment since the Food and Drug Administration (FDA) approved it for weight loss in ...

Nvov Nordisk stock rose after a study showed Ozempic reduced the risk of heart attack, stroke and death by 23% compared with ...

Novo Nordisk A/S rose the most in a month after its diabetes blockbuster Ozempic beat Eli Lilly & Co.’s older drug Trulicity ...

A senior Novo Nordisk executive on Wednesday described the drugmaker's ongoing trial of its blockbuster obesity medicine for ...

In a new study, Ozempic-maker Novo Nordisk shows that its weight loss pill could achieve the similar efficacy as injectables.

Rybelsus is approved to treat type 2 diabetes but can now officially list its heart benefits as well.

Canadians now have a comprehensive, convenient home delivery option for Ozempic® and Wegovy® prescriptions MISSISSAUGA, ON, ...

The Danish drugmaker said it needed to streamline operations and become more agile, as it faces a more competitive and ...

Novo Nordisk (NVO) shares rose 6% premarket on Thursday after a real-world study showed its diabetes drug Ozempic ...

Novo Nordisk has a strong financial position and portfolio of weight-loss and diabetes treatments. See why NVO’s stock dip ...